Furthermore, using similar dosage regimens, the TLR7 agonist, Imiquimod, reduced experimental autoimmune encephalomyelitis and increased splenic IFN-β production16. This evidence concerns the gene TLR7 and experimental autoimmune encephalomyelitis.